Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 18413813)

1.

Targeting Ras in myeloid leukemias.

Braun BS, Shannon K.

Clin Cancer Res. 2008 Apr 15;14(8):2249-52. doi: 10.1158/1078-0432.CCR-07-1005. Review.

2.

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Parikh C, Subrahmanyam R, Ren R.

Blood. 2006 Oct 1;108(7):2349-57. Epub 2006 Jun 8.

3.

Mouse model for NRAS-induced leukemogenesis.

Parikh C, Ren R.

Methods Enzymol. 2008;439:15-24. doi: 10.1016/S0076-6879(07)00402-8.

PMID:
18374153
4.

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Parikh C, Subrahmanyam R, Ren R.

Cancer Res. 2007 Aug 1;67(15):7139-46.

5.

Ras processing as a therapeutic target in hematologic malignancies.

Le DT, Shannon KM.

Curr Opin Hematol. 2002 Jul;9(4):308-15. Review.

PMID:
12042705
6.

Differential oncogenic potential of activated RAS isoforms in melanocytes.

Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL.

Oncogene. 2007 Jul 5;26(31):4563-70. Epub 2007 Feb 5.

PMID:
17297468
7.

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.

Lauchle JO, Braun BS, Loh ML, Shannon K.

Pediatr Blood Cancer. 2006 May 1;46(5):579-85. Review.

PMID:
16261595
8.

The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.

Rotblat B, Ehrlich M, Haklai R, Kloog Y.

Methods Enzymol. 2008;439:467-89. doi: 10.1016/S0076-6879(07)00432-6.

PMID:
18374183
9.

Ras signaling and therapies.

Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F.

Adv Cancer Res. 2009;102:1-17. doi: 10.1016/S0065-230X(09)02001-6. Review.

PMID:
19595305
10.

Network analysis of oncogenic Ras activation in cancer.

Stites EC, Trampont PC, Ma Z, Ravichandran KS.

Science. 2007 Oct 19;318(5849):463-7.

11.
12.
13.

The Ras signaling pathway and the molecular basis of myeloid leukemogenesis.

Shannon K.

Curr Opin Hematol. 1995 Jul;2(4):305-8. Review. No abstract available.

PMID:
9372012
14.

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, Tamura A, Honda H, Sakata-Yanagimoto M, Kumano K, Oda H, Yamagata T, Takita J, Gotoh N, Nakazaki K, Kawamata N, Onodera M, Nobuyoshi M, Hayashi Y, Harada H, Kurokawa M, Chiba S, Mori H, Ozawa K, Omine M, Hirai H, Nakauchi H, Koeffler HP, Ogawa S.

Nature. 2009 Aug 13;460(7257):904-8. doi: 10.1038/nature08240. Epub 2009 Jul 20.

PMID:
19620960
15.

Targeting oncogenic Ras signaling in hematologic malignancies.

Ward AF, Braun BS, Shannon KM.

Blood. 2012 Oct 25;120(17):3397-406. doi: 10.1182/blood-2012-05-378596. Epub 2012 Aug 16. Review.

16.

ras proteins and the ras-related signal transduction pathway.

Janowski M.

Radiat Environ Biophys. 1991;30(3):185-9. Review.

PMID:
1924703
17.

Interactions of Ras proteins with the plasma membrane and their roles in signaling.

Eisenberg S, Henis YI.

Cell Signal. 2008 Jan;20(1):31-9. Epub 2007 Aug 21. Review.

PMID:
17888630
18.

Endogenous K-ras signaling in erythroid differentiation.

Zhang J, Lodish HF.

Cell Cycle. 2007 Aug 15;6(16):1970-3. Epub 2007 Jun 10.

19.

Deregulated Ras signaling in developmental disorders: new tricks for an old dog.

Schubbert S, Bollag G, Shannon K.

Curr Opin Genet Dev. 2007 Feb;17(1):15-22. Review.

PMID:
17208427
20.

Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells.

Espino PS, Pritchard S, Heng HH, Davie JR.

Int J Cancer. 2009 Feb 1;124(3):562-7. doi: 10.1002/ijc.23959.

PMID:
19004007
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk